Drug Trial News RSS Feed - Drug Trial News

Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients

Estrogen receptor degrader increases progression-free survival in advanced breast cancer patients

Fulvestrant significantly increases progression-free survival in women with hormone-receptor-positive advanced breast cancer, particularly those with less aggressive lower-volume disease, researchers reported at the ESMO 2016 Congress in Copenhagen [More]
Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ breast cancer patients

Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ breast cancer patients

The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen. [More]
PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

PARP inhibitor prolongs progression-free survival in patients with recurrent ovarian cancer

The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to full data from the ENGOT-OV16/NOVA trial presented for the first time at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine. [More]
Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy redefines treatment approach for metastatic bladder cancer patients

Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO 2016 Congress in Copenhagen. [More]
Immune checkpoint inhibitor as adjuvant therapy improves overall survival in patients with stage III melanoma

Immune checkpoint inhibitor as adjuvant therapy improves overall survival in patients with stage III melanoma

Ipilimumab as adjuvant therapy significantly improves overall survival in patients with high risk stage III melanoma, according to the EORTC 18071 phase III trial results presented for the first time today at the ESMO 2016 Congress in Copenhagen. [More]
Researchers report high response rate with single drug in phase I/II trial of paediatric brain cancer

Researchers report high response rate with single drug in phase I/II trial of paediatric brain cancer

A high response rate with a single drug in a phase I/II trial of paediatric brain tumour has set the stage for combination therapy with higher response and lower toxicity, researchers reported at the ESMO 2016 Congress in Copenhagen. [More]
UAB researchers launch first drug study to prevent onset of epilepsy in children with TSC

UAB researchers launch first drug study to prevent onset of epilepsy in children with TSC

Researchers at the University of Alabama at Birmingham have launched the first drug study aimed at preventing or delaying the onset of epilepsy in children with a genetic condition known as tuberous sclerosis complex. [More]
GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients with mild to moderate Alzheimer's disease. [More]
ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

The Alzheimer's Drug Discovery Foundation announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna for use as a cancer therapy) in patients with Alzheimer's disease. [More]
Clinical study to test efficacy of different formulations of flu vaccine in heart failure patients

Clinical study to test efficacy of different formulations of flu vaccine in heart failure patients

Heart disease patients enrolled in a clinical trial - designed to test whether a stronger dose of the influenza vaccine can prevent death or hospitalization due to a heart attack, heart failure, stroke or pneumonia - have begun receiving their first flu shots in Toronto and Boston. [More]
New study to examine effectiveness of orally administered drug in treating stuttering

New study to examine effectiveness of orally administered drug in treating stuttering

Stuttering, an interruption in the flow of speech, affects about three million Americans. It begins most often in childhood, affecting four men for every woman. A precise cause of this complex communicative disorder is not known. [More]
New partnership between BetterYou and University of Sheffield paves way for vitamin D research

New partnership between BetterYou and University of Sheffield paves way for vitamin D research

A new collaboration between health pioneers BetterYou and scientists from the University of Sheffield, is paving the way for a three-year clinical trial looking at the effect of vitamin D supplementation on the quality of life of people with Irritable Bowel Syndrome (IBS). [More]
Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

Clinical trial to examine effectiveness of diabetes drug to slow or stop progression of Parkinson's

Type II diabetes and Parkinson's disease may not appear to have much in common but a look below the surface reveals important molecular similarities that provide a potential target for fighting Parkinson's. [More]
Changing dosing regimen could improve efficacy of malaria vaccine candidate, study shows

Changing dosing regimen could improve efficacy of malaria vaccine candidate, study shows

Researchers at the Walter Reed Army Institute of Research and collaborators recently published results of a phase II study which demonstrated that by changing the dosing regimen, the efficacy of malaria vaccine candidate, RTS,S/AS01, was improved to approximately 87%, compared with 63% using the current standard regimen. [More]
Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Monoclonal antibody removes brain amyloid plaques in patients with Alzheimer's disease

Scientists at Neurimmune today described results from the Phase 1b PRIME clinical trial of the monoclonal antibody aducanumab. [More]
HIJ-PROPER trial: Intensive cholesterol-lowering regimen in ACS patients shows no better outcomes

HIJ-PROPER trial: Intensive cholesterol-lowering regimen in ACS patients shows no better outcomes

Survival and other cardiovascular outcomes were not significantly reduced with intensive treatment using a second-line cholesterol-lowering medication on top of a standard statin, compared to statin treatment alone in patients with acute coronary syndrome (ACS) and dyslipidemia, investigators reported here. [More]
Leading Chikungunya vaccine in clinical trial phase 2

Leading Chikungunya vaccine in clinical trial phase 2

With the first patient vaccinated, a Phase 2 clinical trial of a promising prophylactic vaccine candidate against Chikungunya fever has now commenced. The product is the most advanced Chikungunya vaccine candidate globally and is developed by the Austrian biotech company Themis Bioscience GmbH. [More]
NEJM publishes MINDACT trial results

NEJM publishes MINDACT trial results

Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announces the peer-reviewed publication of the primary outcome results of the Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy (MINDACT) clinical trial in the prestigious New England Journal of Medicine (NEJM). (i, iii, iv) The publication demonstrates that 46% of breast cancer patients considered for chemotherapy, whose tumors are classified MammaPrint Low Risk, have excellent survival without chemotherapy, and can thus be candidates to avoid this toxic therapy. [More]
BirchBioMed announces successful completion of Phase I trial for topical treatment to prevent scarring

BirchBioMed announces successful completion of Phase I trial for topical treatment to prevent scarring

BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia researchers to prevent scarring has completed a Health Canada approved Phase I trial. [More]
Fiocruz to start phase II clinical trials of novel vaccine for schistosomiasis

Fiocruz to start phase II clinical trials of novel vaccine for schistosomiasis

The Oswaldo Cruz Foundation at Rio de Janeiro, Brazil, will start the phase II clinical trials of a vaccine for schistosomiasis, called 'Sm14 Vaccine'. [More]
Advertisement
Advertisement